Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
arcticnovartis
Thu, 04/30/2026 – 13:04
Read more about Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
…
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
arcticnovartis
Thu, 04/30/2026 – 13:04
Read more about Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
…
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
arcticnovartis
Thu, 04/30/2026 – 13:04
Read more about Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
…
Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt
arcticnovartis
Tue, 04/28/2026 – 07:03
Read more about Novartis erzielte im ersten Quartal mit prio…
Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt
arcticnovartis
Tue, 04/28/2026 – 07:03
Read more about Novartis erzielte im ersten Quartal mit prio…
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
arcticnovartis
Tue, 04/28/2026 – 07:03
Read more about Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance rea…
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
arcticnovartis
Mon, 04/27/2026 – 07:19
Read more about Novartis Rhapsido® receives European …
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
arcticnovartis
Mon, 04/27/2026 – 07:19
Read more about Novartis Rhapsido® receives European …
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
arcticnovartis
Mon, 04/27/2026 – 07:19
Read more about Novartis Rhapsido® receives European …
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
arcticnovartis
Mon, 04/27/2026 – 07:19
Read more about Novartis Rhapsido® receives European …
